Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E19.85 EPS (ttm)7.55 Insider Own0.10% Shs Outstand758.25M Perf Week6.90%
Market Cap113.66B Forward P/E13.96 EPS next Y10.74 Insider Trans-7.82% Shs Float756.23M Perf Month-0.78%
Income5.81B PEG1.65 EPS next Q2.38 Inst Own81.70% Short Float1.38% Perf Quarter-2.27%
Sales20.77B P/S5.47 EPS this Y0.90% Inst Trans0.00% Short Ratio2.55 Perf Half Y-7.37%
Book/sh36.16 P/B4.15 EPS next Y10.01% ROA8.30% Target Price185.23 Perf Year9.03%
Cash/sh39.56 P/C3.79 EPS next 5Y12.00% ROE22.10% 52W Range125.31 - 180.97 Perf YTD-4.49%
Dividend3.16 P/FCF18.07 EPS past 5Y8.20% ROI10.20% 52W High-17.17% Beta0.67
Dividend %2.11% Quick Ratio5.10 Sales past 5Y6.50% Gross Margin79.90% 52W Low19.62% ATR5.45
Employees17900 Current Ratio5.50 Sales Q/Q3.70% Oper. Margin36.80% RSI (14)52.75 Volatility4.14% 3.56%
OptionableYes Debt/Eq1.16 EPS Q/Q7.00% Profit Margin28.00% Rel Volume1.62 Prev Close148.05
ShortableYes LT Debt/Eq1.12 EarningsOct 28 AMC Payout36.60% Avg Volume4.09M Price149.90
Recom2.40 SMA203.16% SMA50-3.47% SMA200-4.56% Volume6,635,321 Change1.25%
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Oct-08-15 04:43PM  3 Pharma Stocks With Big Margins of Safety at Motley Fool
04:06PM  Stocks Rally as March Rate Hike Most Likely at TheStreet
02:55PM  Stocks Rise as Investors Interpret Fed Minutes as Dovish at TheStreet
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie
08:49AM  Biogen Caused Biotech Collapse but Might Also Lead Stocks Higher at TheStreet
Oct-07-15 04:46PM  Amgen's 1990 Base Breakout Launched Major Price Move at Investor's Business Daily
04:31PM  US STOCKS-S&P 500 reaches three-week high as health stocks rally
03:37PM  US STOCKS-Wall St rises as health care rebounds
03:10PM  Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay
01:07PM  BioMarin Pharmaceutical Takes a Nosedive Last Week
12:23PM  Retail upgrade bolsters Lululemon shares at Financial Times
12:02PM  Cholesterol Busters Will Be Cheaper but Remain Top Sellers at Motley Fool
11:35AM  Regeneron, Amgen Up As PCSK9s Gain Key Coverage at Investor's Business Daily
10:02AM  Are Cholesterol Drugs In For Another Revolution? at Investor's Business Daily
09:30AM  The Zacks Analyst Blog Highlights: CVS Health, Amgen, Eli Lilly, AbbVie and Teva Pharmaceutical
08:03AM  Amgen Turning the Tables on 'Generic' Competition at Motley Fool
12:40AM  Express Scripts to Cover Both New Cholesterol Drugs at The Wall Street Journal
Oct-06-15 10:09PM  Express Scripts to Cover Both New Cholesterol Drugs at The Wall Street Journal
05:25PM  Express Scripts agrees deal for heart drugs at Financial Times
05:10PM  Express Scripts Says It Will Save America Money On New Cholesterol Drugs, But Its Math Doesn't Check Out at Forbes
05:06PM  Amgen Announces Repatha Co-Preferred Position on Express Scripts National Formulary PR Newswire
05:00PM  How Express Scripts plans to cover a $14,000 drug at CNBC
05:00PM  Express Scripts sees $750 mln in spending on new cholesterol drugs
04:11PM  Biotech stocks fall on trade deal and drug price scrutiny
04:07PM  How to play the biotech index: Pro
03:24PM  Moody's: Spotlight on US drug prices poses limited risk to pharmaceutical industry earnings for now at Moody's
02:36PM  Biotech stocks fall as drug prices remain under scrutiny
01:48PM  Is Amgen Threatened By Novartis Enbrel Biosimilar?
12:56PM  Drug Price Worries Derail Biotech StocksAgain at The Wall Street Journal
11:41AM  Juno is Inches Away From Stunning the World
09:15AM  Amgen To Give 23 Presentations On Osteoporosis Disease And Treatment At American Society For Bone And Mineral Research Annual Meeting PR Newswire
Oct-05-15 06:14PM  Novartis' (NVS) Sandoz Files for Enbrel Biosimilar in the U.S.
03:17PM  Trans-Pacific Partnership May Face Tough Sledding In the House at Forbes
11:58AM  Biotech: Sentiment Still Tenuous? at
Oct-04-15 10:01AM  3 Rock-Solid Dividend Stocks You Can Buy Right Now at Motley Fool
Oct-03-15 01:29AM  The Volatility Lovers at
Oct-02-15 04:01PM  Amgen To Present At The Barclays Biosimilars Symposium PR Newswire
03:00PM  Where's the Best Risk-Reward in Biotech? at
12:03PM  Amgen Is In Novartis' Crosshair at Motley Fool
03:31AM  Novartis biosimilar copycat takes aim at Amgen's drug Enbrel Reuters
Oct-01-15 05:00PM  Trading hedge fund bottoms: 4 plays
10:50AM  Can You Guess Which Surprising Company Is Trying to Become a Cardiovascular Drug Giant? at Motley Fool
10:22AM  Biotech: Out of the Ashes at
Sep-30-15 04:10PM  Express Scripts says Praluent, Repatha will not be "budget busters" Reuters
03:08PM  Johnson & Johnsons Pharmaceuticals Segment Grows in 2Q15
02:25PM  XBIs Moving Averages: The Massive Plummet Last Week
02:09PM  Biotech: Will Valuation End the Carnage? at
09:30AM  The Zacks Analyst Blog Highlights: Express Scripts, AbbVie, Amgen, Anika Therapeutics and PDL BioPharma
Sep-29-15 05:14PM  U.S. biotech bloodbath hits hedge funds but some bargains emerge
03:27PM  Biotech creeps higher
02:50PM  Price controls on biotech do not work: Pro
11:38AM  Here Is Why Amgen Is A Steal At Current Price
11:25AM  Independent Research Sees 3 Top Health and Biotech Stocks as Oversold at 24/7 Wall St.
10:10AM  Stock Market News for September 29, 2015
09:46AM  Gilead Sciences: How Bad Can It Get? at
09:30AM  The Zacks Analyst Blog Highlights: Fitbit, Hain Celestial Group, Nautilus and Amgen
09:10AM  Regeneron Pharmaceuticals and Sanofi Grab Another Important Win at Motley Fool
Sep-28-15 04:35PM  Regeneron/Sanofi's PCSK9 Inhibitor Praluent Approved in EU
03:59PM  Tough to Buy Stocks With More Declines Likely on the Way at TheStreet
02:04PM  Step away from biotechs, let dust settle: Pro
01:19PM  Business events scheduled for Tuesday
12:22PM  Biotech ETFs Continue To Get Bludgeoned at Investor's Business Daily
11:35AM  4 Fit & Healthy Stocks to Love on World Heart Day
10:30AM  Biotech: Does Anyone Care That Fundamentals Remain Strong? at
10:23AM  In Volatile Markets, Short Sellers Head For Biotechs
10:04AM  Right Now: Gilead is Suddenly Impossible to Ignore
07:00AM  Stock Market Outlook: Minor Correction Not Enough to Make Stocks Cheap at Morningstar
Sep-26-15 09:25AM  How the Top Biotechs Handled the Valuation Shock at 24/7 Wall St.
Sep-25-15 03:19PM  5 Key Drugs That Just Won EU Endorsements at Investor's Business Daily
11:59AM  The Price War for New Cholesterol Drugs Is Heating Up at Motley Fool
08:35AM  Amgen's leukemia drug gets conditional European approval Reuters
08:05AM  Short Sellers Increase Bets in Major Biotech at 24/7 Wall St.
07:27AM  Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe PR Newswire
07:08AM  Amgen May Be Near a Bottom at TheStreet
Sep-24-15 08:06PM  Stock Market Today - 09/24/15
04:30PM  Amgen, Allergan's Biosimilar of Avastin Tops Phase III Study
11:34AM  Activist Hedge Fund Manager Dan Loeb Decreases Position in Leading Biotech Company
10:39AM  Biotech: Two Charts That Scream Sell at
09:30AM  The Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACONThe Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACON
08:38AM  Will the FDA Approve All 3 of These Cancer Drugs in October? at Motley Fool
08:03AM  Amgen Gets a Step Closer to a Multibillion-Dollar Market at Motley Fool
Sep-23-15 05:44PM  Amgen, Allergan Biosimilar Avastin Hits In Trial at Investor's Business Daily
05:15PM  Amgen, Allergan say their Avastin biosimilar showing positive results at
04:07PM  Amgen looks spectacular: Pro
12:37PM  Biotech Stock Roundup: Clinton's Tweet Shakes Biotech Stocks, Amgen In Pipeline-Boosting Deals
11:23AM  Price-Gouging Issue Ignites Fresh Focus On Biotechs at Forbes
10:43AM  Amgen, Allergan say Avastin copycat succeeds in lung cancer study Reuters
10:10AM  Stock Market News for September 23, 2015
09:56AM  Amgen, Allergan Biosimilar Lung-Cancer Therapy Shows Positive Results at The Wall Street Journal
09:00AM  Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215 PR Newswire
08:04AM  Amgen's Billion-Dollar Cholesterol-Curbing Bet at Motley Fool
12:08AM  New Weapon in Push to Lower U.S. Biotech Drug Prices at The Wall Street Journal
Sep-22-15 08:14PM  New Weapon in Push to Lower Biotech Drug Prices at The Wall Street Journal
04:42PM  5 Biotech Stocks Hit Hard by Hillary Clinton's Tweet
04:28PM  Apple Gets Bullish Call; Nike, Amgen PTs Raised at Investor's Business Daily
03:49PM  Biotech: Reaction to Clinton Plan 'Premature' at
02:58PM  Hillary Keeps Pressuring Biotechs, But AutoZone Gets Earnings Lift at Investor's Business Daily
02:30PM  Amgen's 2018 Repatha Sales Estimates Hiked 60% at Investor's Business Daily
11:07AM  Regeneron and Amgen Pull Down Biotechnology
10:04AM  Amgen & Regeneron: No, Clinton Tweet Won't Kill Anti-Cholesterol Drugs at
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has strategic collaboration with Xencor, Inc.; and collaborative agreements with AstraZeneca Plc, Takeda Pharmaceutical Company Limited, UCB, Novartis AG, and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorAug 31Sale153.845,000769,19215,150Sep 02 07:46 PM
Hassan FredDirectorAug 19Buy166.633,010501,5623,582Aug 20 05:58 PM
PELHAM JUDITH CDirectorJul 31Sale180.405,035908,31411,890Aug 04 06:31 PM
Patton Cynthia MSVP & CCOJun 02Sale157.064,530711,48216,571Jun 03 07:16 PM
Balachandran MadhavanEVP, OperationsMay 07Option Exercise55.7221,7501,211,94855,144May 11 04:56 PM
Balachandran MadhavanEVP, OperationsMay 07Sale157.8721,7503,433,69533,394May 11 04:56 PM
Tross Stuart ASVP, Human ResourcesApr 23Sale169.313,012509,96421,923Apr 24 04:53 PM
Harper Sean EEVP, Research & DevelopmentApr 22Sale171.5828,0004,804,24047,920Apr 23 05:04 PM
Tross Stuart ASVP, Human ResourcesMar 03Sale157.744,415696,42720,237Mar 04 08:25 PM
BALTIMORE DAVIDDirectorMar 02Sale158.763,647579,01131,159Mar 03 08:55 PM
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM
COFFMAN VANCE DDirectorFeb 06Option Exercise42.135,000210,65038,460Feb 06 06:23 PM
HERRINGER FRANK CDirectorFeb 05Option Exercise42.135,000210,65025,449Feb 05 08:11 PM
HERRINGER FRANK CDirectorFeb 05Buy152.293,000456,8702,000Feb 05 08:11 PM
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM